#FabtechIPO #StockMarketNews #IPOUpdate #IndianMarket #Biopharma #TurnkeySolutions #RetailBidding #NSE #BSE #InvestmentNews
Mumbai, India – Fabtech Technologies Limited’s Initial Public Offering (IPO) saw its subscription rate cross the one-time mark on the second day of bidding, driven primarily by strong participation from retail investors. As of the close of Day 2, the total issue was subscribed 1.01 times, with the retail segment leading the charge.
The ₹230-crore IPO, which is an entirely fresh issue of 1.21 crore equity shares, is set to close on Wednesday, October 1, 2025. The price band for the offer is fixed at ₹181 to ₹191 per equity share.
Category-Wise Subscription
Data from the exchanges indicates that the portion reserved for Retail Individual Investors (RIIs) was fully subscribed, reaching 1.20 times the shares on offer. This suggests robust interest from small investors looking to gain exposure to the specialized biopharma engineering solutions sector.
The Qualified Institutional Buyers (QIBs) segment saw bids for 0.94 times of its allocated quota. Institutional participation typically picks up significantly on the final day, and analysts anticipate this category will be fully subscribed by the closing date. The Non-Institutional Investors (NIIs), which include high-net-worth individuals, have subscribed to 0.76 times of their reserved portion.
Grey Market Premium (GMP) and Analyst View
Initial market sentiment, as reflected in the unofficial Grey Market Premium (GMP), has shown fluctuations. On the first day, the GMP was reported as high as 18%, suggesting a healthy expected listing gain. However, the premium has since moderated, with some reports now indicating a marginal premium, reflecting a more cautious near-term outlook for the stock.
Analysts have offered mixed, though generally positive, views on the IPO. While some brokerage firms have assigned a ‘Neutral’ rating, citing the “fully priced” valuation at the upper end of the band, others recommend subscribing with a medium to long-term perspective. Fabtech’s strengths are highlighted by its asset-light business model, a healthy order book of over ₹760 crore, and its global presence as a turnkey engineering solutions provider for the pharmaceutical and biotech industries.
Company Profile and IPO Objectives
Fabtech Technologies is an India-headquartered global company specializing in providing end-to-end engineering solutions—from design to commissioning—for cleanroom facilities, modular systems, and bio-pharma process systems. The company operates in more than 60 countries, catering to the life sciences, food & beverage, and healthcare sectors.
The net proceeds from the IPO are planned for a few strategic purposes: a major chunk is allocated for working capital requirements (₹127 crore), which will support the company’s execution of its large order book. A smaller but significant portion (₹30 crore) is earmarked for inorganic growth initiatives through acquisitions, with the remainder reserved for general corporate purposes.
Investors have until the end of Wednesday, October 1, 2025, to submit their bids. The shares are tentatively scheduled to be listed on both the BSE and NSE on October 7, 2025.
#FabtechIPO #StockMarketNews #IPOUpdate #IndianMarket #Biopharma #TurnkeySolutions #RetailBidding #NSE #BSE #InvestmentNews
